Our current study indicates that LCN2 could be a promising target for CCA treatment, since it acts as an oncogene in CCA cells in vitro and in vivo, and higher LCN2 expression is linked to poor OS of patients with CCA. Here, LCN2 is linked to cholangiocarcinoma.